Clinical trials: Febrile Neutropenia, Drug-Induced
Acute Myeloid Leukemia
Evaluation of Infective Risk, Efficacy of Bacterial Prophylaxis and Validation of Sepsis Scores NEWS (National Early Warning Score) and qSOFA (Quick Sequential Organ Failure Assessment) in Patient With Acute Myeloid Leukemia Treated With Intensive Chemotherapy
Evaluation of Infective Risk, Efficacy of Bacterial Prophylaxis and Validation of sepsis scores NEWS (National Early Warning Score) and qSOFA (Quick Sequential Organ Failure Assessment) in Patient With Acute Myeloid Leukemia…
- Trial name
- LAM-SEPSIS (NCT05249894)
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Non-Interventional Study
Home Administration of NivestimTM in the Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia
Non-interventional, non-comparative, national, multi-site, single-arm prospective observational study to investigate home administration of Nivestim in the primary prophylaxis of chemotherapy-Induced febrile neutropenia
- Trial name
- NCT02956967
- Testing
- Overall satisfaction questionnaires of home use of Nivestim
- Where
- 28 sites in Germany
- Volunteers
- 171 people
- Sponsor
- Pfizer
Fever, Sweats, and Hot Flashes, Neutropenia
Antibiotic Therapy With or Without G-CSF in Treating Children With Neutropenia and Fever Caused by Chemotherapy
RATIONALE: Antibiotics may decrease the side effects of neutropenia and fever caused by chemotherapy. Colony-stimulating factors such as G-CSF may increase the number of immune cells found in bone marrow or peripheral blood and…
- Conditions
- Fever, Sweats, and Hot Flashes, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00003739
- Testing
- filgrastim
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 67 people
- Sponsor
- Children's Oncology Group
Chemotherapy-induced Neutropenia
Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN
The present study was an observational, multicenter, non-interventional, single arm, open label, PMS study conducted in Iran. The primary objective of this study was safety assessment, including the rate of AEs.
- Trial name
- NCT04460079
- Testing
- Peg-filgrastim
- Volunteers
- 654 people
- Sponsor
- Cinnagen
Chemotherapy-induced Febrile Neutropenia
Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.
This is a prospective observational study investigating how physicians assess the risk of febrile neutropenia (FN) developing in patients who will receive chemotherapy.
- Trial name
- NCT01813721
- Where
- 90 sites in Australia, Austria and 9 more
- Volunteers
- 1,007 people
- Sponsor
- Amgen
Neutropenia, Chemotherapy-Induced Febrile, Breast Neoplasm Female
Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy
To evaluate the efficacy, safety, and immunogenicity of PEG-G-CSF Injection (Kexing Biopharmaceutical Co., Ltd.) for the prevention of neutropenia after chemotherapy, using the PEG-G-CSF Injection ( Neulasta®, Amgen Europe B.V.)…
- Trial name
- NCT06711523
- Testing
- PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.), PEG-G-CSF injection (Neulasta®，Amgen Europe B.V.)
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Kexing Biopharm Co., Ltd.
Breast Neoplasms, Chemotherapy-Induced Febrile Neutropenia
Efficacy and Safety Study With MYL-1401H and Neulasta
This is a Multicenter, Double-Blind, Randomized, Comparative Efficacy and Safety Study of MYL-1401H and Neulasta (Pegfilgrastim) in Stage II/III Breast Cancer Patients Receiving Neoadjuvant or Adjuvant Chemotherapy.
- Trial name
- NCT02467868
- Testing
- MYL-1401H, Neulasta
- Where
- 36 sites in Bulgaria, Georgia and 4 more
- Volunteers
- 193 people
- Sponsor
- Mylan Inc.
Patient Preference, Febrile Neutropenia, Drug-Induced
Patient Preference Between a Prefilled Syringe or a Prefilled Pen Device for Administration of Pegfilgrastim
Febrile neutropenia (NF) is a common serious complication of cancer chemotherapy. Outpatient management of chemotherapy treatments is made essential by the volume of patients treated, respect for their quality of life and the…
- Conditions
- Patient Preference, Febrile Neutropenia, Drug-Induced, Patient Satisfaction
- Trial name
- PELGRAZ (NCT05910164)
- Testing
- PELGRAZ prefilled syringe or PELGRAZ prefilled pen
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Institut Rafael
Chemotherapy-induced Febrile Neutropenia
Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy
To estimate the incidence of febrile neutropenia in patients with breast cancer and non-Hodgkin's lymphoma receiving high (> 20%) FN-risk chemotherapy and pegfilgrastim primary prophylaxis.
- Trial name
- NCT02178475
- Where
- 74 sites in Austria, Belgium and 7 more
- Volunteers
- 943 people
- Sponsor
- Amgen
Chemotherapy-Induced Febrile Neutropenia
Safety and Efficacy of Ambulatory Versus In-hospital Antibiotic Treatment in Children With Febrile Neutropenia
Febrile neutropenia (FN) continues to be the infectious complication that most commonly requires hospitalization in pediatric cancer patients undergoing chemotherapy.
- Trial name
- NCT04000711
- Testing
- Outpatient oral treatment., Inpatient intravenous treatment.
- Volunteers
- 117 people
- Sponsor
- Hospital Infantil de Mexico Federico Gomez
Chemotherapy-Induced Febrile Neutropenia
Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints
The goal of this real-world study is to compare the efficacy and safety of QL0605 administered 24 hours and 48 hours after chemotherapy in breast cancer patients.
- Trial name
- NCT06616571
- Testing
- QL0605(PEG-rhG-CSF)
- Where
- China
- Volunteers
- 336 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Early Stage Breast Cancer
A Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Febrile Neutropenia
In patients with early-stage breast cancer, chemotherapy has substantially improved survival rates. Improvements in outcomes, however, are compromised by the considerable toxicities associated with chemotherapy, the most notable…
- Trial name
- REaCT-G2 (NCT02816164)
- Testing
- Neupogen
- Where
- Canada
- Volunteers
- 324 people
- Sponsor
- Ottawa Hospital Research Institute
Solid Tumors, Malignant Hemopathy
Nivestim® (Filgrastim) Tolerance in Patients Treated by Toxic Chemotherapeutic Agents
The main aim of the study is to assess the safety of Nivestim® treatment in patients treated with neutropenia-inducing chemotherapy for a malignant disease, solid tumor or a malignant hemopathy.
- Conditions
- Solid Tumors, Malignant Hemopathy, Chemotherapy-induced Febrile Neutropenia (FN)
- Trial name
- NCT01574235
- Testing
- Nivestim®
- Where
- 87 sites in France
- Volunteers
- 2,114 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Granulocyte Colony-Stimulating Factor, Chemotherapy-induced Neutropenia
Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer Patients
Chemotherapy places patients at an increased risk of infection. A medication called granulocyte colony-stimulating factor is given as a daily injection in order to help decrease the risk of infection.
- Conditions
- Granulocyte Colony-Stimulating Factor, Chemotherapy-induced Neutropenia, Chemotherapy-Induced Febrile Neutropenia, Pediatric Cancer
- Trial name
- NCT03823950
- Testing
- Granulocyte Colony-Stimulating Factor
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Mississippi Medical Center
Febrile Neutropenia, Cancer
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
This international, prospective, observational, open-label, pharmaco-epidemiologic study observes cancer patients at risk for chemotherapy-induced febrile neutropenia (FN) who are receiving filgrastim biosimilar (EP2006) for…
- Conditions
- Febrile Neutropenia, Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- Monitor-GCSF (NCT01459653)
- Where
- 117 sites in Austria, Belgium and 10 more
- Volunteers
- 1,496 people
- Sponsor
- Sandoz
Febrile Neutropenia, Drug-Induced
Predictive Value of ProCalcitonin for the Detection of Bacteraemia in Patients Presenting to the Emergency Department for Low Risk Chemo-induced Febrile Neutropenia
CALIF study is a monocentric observational study which aim is to analyse the value of adding procalcitonin (PCT, a pre-hormon increased in bacterial infection and septicaemia) in the management of chemo-induced febrile…
- Trial name
- CALIF (NCT03182465)
- Testing
- Value of ProCalcitonin
- Where
- Belgium
- Volunteers
- 54 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Febrile Neutropenia, Febrile Neutropenia, Rule of Clinical Decision, Chemotherapy
Comparison of G-CSF & Antibiotics Versus Antibiotics Alone in Resolution of Febrile Neutropenia
This study aim to find the best option for children having cancer who develop low immunity state due to chemotherapy
- Conditions
- Febrile Neutropenia, Febrile Neutropenia, Rule of Clinical Decision, Chemotherapy, Febrile Neutropenia, Drug-Induced, G-CSF
- Trial name
- AGF-FN (NCT06988826)
- Testing
- G-CSF, Antibiotics only
- Volunteers
- 150 people
- Sponsor
- King Edward Medical University
Early Stage Breast Cancer
A Multi Centre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Standard of Care Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (React-G Study)
In patients with early-stage breast cancer, chemotherapy has substantially improved survival rates for breast cancer patients. Improvements in outcomes, however, are compromised by the considerable toxicities associated with…
- Trial name
- React-G (NCT02428114)
- Where
- 2 sites in Canada
- Volunteers
- 142 people
- Sponsor
- Ottawa Hospital Research Institute
Chemotherapy-induced Neutropenia, Febrile Neutropenia, Drug-Induced
Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer
This study aims to analyze the effects of long-acting versus short-acting granulocyte colony stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in epithelial ovarian cancer patients.
- Conditions
- Chemotherapy-induced Neutropenia, Febrile Neutropenia, Drug-Induced, Epithelial Ovarian Cancer, Colony Stimulating Factors Adverse Reaction
- Trial name
- NCT04101760
- Testing
- Long-acting granulocyte colony stimulating factor, Short-acting granulocyte colony stimulating factor
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Lei Li